EDWARDS LIFESCIENCES CORPORATION (NYSE:EW) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
EDWARDS LIFESCIENCES CORPORATION (NYSE:EW) Files An 8-K Results of Operations and Financial Condition
On July 23, 2019, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second>quarter of 2019. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference.
The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
Edwards Lifesciences Corp Exhibit
EX-99.1 2 ex-991q22019.htm EXHIBIT 99.1 Exhibit Edwards Lifesciences CorporationOne Edwards Way · Irvine,…
To view the full exhibit click
EX-99.1 2 ex-991q22019.htm EXHIBIT 99.1 Exhibit Edwards Lifesciences CorporationOne Edwards Way · Irvine,…
To view the full exhibit click
hereAbout EDWARDS LIFESCIENCES CORPORATION (NYSE:EW)
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Company conducts operations around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.
